At A Glance
- Cagrilintide is a longer-acting version of amylin, a hormone released alongside insulin. It attracts interest because amylin is part of the conversation about meals, fullness, and food intake.
- Cagrilintide showed clinical activity in a study of adults with overweight or obesity.
- Researchers pair cagrilintide with semaglutide to explore complementary food-related signals.
What Is CAGRILINTIDE?
Cagrilintide is a longer-acting version of amylin, a hormone released alongside insulin. It attracts interest because amylin is part of the conversation about meals, fullness, and food intake.
Amylin-related receptors help carry signals about satiety—the feeling that you have had enough to eat—and stomach emptying. Cagrilintide explores that route over a longer period. It is a different route from GLP-1, even though some of the topics overlap.
Why Is Cagrilintide Often Mentioned With Semaglutide?
The pairing, known as CagriSema, explores whether two different meal-related signals can complement one another. Cagrilintide also has its own clinical research, including a 26-week phase 2 trial comparing it with placebo and liraglutide.
Is Cagrilintide A GLP-1 Peptide?
It is an amylin analogue. Semaglutide is the GLP-1 component in CagriSema. Keeping those roles separate helps explain both the combination and what cagrilintide contributes to the research question on its own.
A Closer Look At CAGRILINTIDE
Here are the key observations and the context that helps explain them. The original sources are linked below if you would like to explore further.
| Study or context | What was explored | What it tells us | Useful context |
|---|---|---|---|
| Human trial | A 26-week phase 2 comparison | Cagrilintide showed clinical activity in a study of adults with overweight or obesity. | The linked trial compared a defined study product with placebo and liraglutide. |
| Combination research | The amylin component of CagriSema | Researchers pair cagrilintide with semaglutide to explore complementary food-related signals. | Combination results describe the pair, not cagrilintide alone. |
Common Questions About CAGRILINTIDE
What is CAGRILINTIDE?+
Cagrilintide is a longer-acting version of amylin, a hormone released alongside insulin. It attracts interest because amylin is part of the conversation about meals, fullness, and food intake.
Why is cagrilintide often mentioned with semaglutide?+
The pairing, known as CagriSema, explores whether two different meal-related signals can complement one another. Cagrilintide also has its own clinical research, including a 26-week phase 2 trial comparing it with placebo and liraglutide.
Is cagrilintide a GLP-1 peptide?+
It is an amylin analogue. Semaglutide is the GLP-1 component in CagriSema. Keeping those roles separate helps explain both the combination and what cagrilintide contributes to the research question on its own.
Sources
Want to go a little deeper? These links take you to the studies and official records behind the guide. Study registries describe the plan; published papers report the findings.
- the peer-reviewed phase 2 trialPeer-reviewed publication · Linked record
A 26-week randomized phase 2 trial compared once-weekly cagrilintide with placebo and liraglutide in adults with overweight or obesity. The results establish a clinical-development signal for that product—not a guaranteed effect for research material.
- Think twice before injecting peptides bought online: unauthorized products can seriously harm youHealth Canada · 2026
For CAGRILINTIDE context, this official Canadian advisory explains why a research-use label does not establish authorization, safety, efficacy, or product quality for human use.
Vote For CAGRILINTIDE
This compound is not currently stocked. Add it to your five-choice catalogue ballot.